CP.TO 1.15VRT -18.06NVDA -7.33TSM -15.23JPM -6.1ZST.TO 0.01HSAV.TO -0.03HSUV.U.TO 0.03
Pfizer Inc (PFE)

NYSE:PFE

Pfizer Inc (PFE)

27.72
-0.00 (0.00%)
as of Sep 14, 2026, 8:00:00 pm Market Open.
583 watching
Icon Financials Financials Icon Analysis Technical Analysis
Interactive Chart
1w 1m 6m 1y
0
Investor Insights
star iconSep 14, 2026, 12:00 am

This summary was created by AI, based on 27 opinions in the last 12 months.

Pfizer Inc. (PFE) is perceived as a defensive stock with an attractive dividend yield around 6-7%, appealing to income-focused investors. However, many experts express concern about the company's growth potential following a reliance on COVID-19 vaccine revenues, which have receded. The consensus indicates that while PFE maintains a low valuation (PE around 8-10x), its growth is stagnant or uncertain due to impending patent expirations and the challenges associated with developing new blockbuster drugs. Moreover, there are worries that the ongoing focus on acquisitions may not lead to the anticipated revenue boosts. Despite these concerns, some analysts suggest PFE could still perform well for patient investors, especially as sector interest begins to build. Ultimately, the outlook remains cautious, with a preference noted for other stocks in the pharmaceutical sector that exhibit better growth trajectories.

consensus icon
Consensus
Cautious
valuation icon
Valuation
Undervalued
review icon
Similar
LLY
PAST TOP PICK

Pfizer Inc(PFE)

Jan 07, 2004
(A past top pick Dec 6/03. Up 6.7%.) Still likes it. A tremendous pipeline. Not facing a lot of patent issues. Very reasonable valuation. Will be a solid 15/20% grower.
Photo of Laura WallaceLaura Wallace
Owned
Unlock Rating
$36.79

Stock price when the opinion was issued

$27.72

As of Sep 14, 2026. Market Open.

biotechnologypharmaceutical
TOP PICK

Pfizer Inc(PFE)

Dec 29, 2003
Pharmaceutical companies have been laggards. Should have revenue growth of about 40% and earnings at about 20% in 2004. 2 1/2% dividend.
Photo of John Sinkins, CFAJohn Sinkins, CFA
Owned
Unlock Rating
$35.00

Stock price when the opinion was issued

$27.72

As of Sep 14, 2026. Market Open.

biotechnologypharmaceutical
HOLD

Pfizer Inc(PFE)

Dec 12, 2003
One of the best pharmaceutical companies. The large pharmaceutical companies are increasingly facing more and more headwinds. If it reaches the upper $30's, consider selling.
Photo of Jonathen Wellum, B. Comm, B. ScJonathen Wellum, B. Comm, B. Sc
Owned
Unlock Rating
$34.40

Stock price when the opinion was issued

$27.72

As of Sep 14, 2026. Market Open.

biotechnologypharmaceutical
TOP PICK

Pfizer Inc(PFE)

Dec 01, 2003
Trading at 15X 2004 earnings. Will have a growth rate of 15/20%. Well diversified number of drugs. Nothing coming off patent until 2007. The whole area has been hit hired on the concerns of US pricing of drugs, but feels the bill will be positive.
Photo of Laura WallaceLaura Wallace
Owned
Unlock Rating
$34.17

Stock price when the opinion was issued

$27.72

As of Sep 14, 2026. Market Open.

biotechnologypharmaceutical
PAST TOP PICK

Pfizer Inc(PFE)

Nov 28, 2003
(A top pick July 10/03. No change.) There is something wrong with the drug stocks. They are all trading poorly and he thinks they want to go lower.
Photo of Ross HealyRoss HealyUnlock Rating
$33.57

Stock price when the opinion was issued

$27.72

As of Sep 14, 2026. Market Open.

biotechnologypharmaceutical
TOP PICK

Pfizer Inc(PFE)

Nov 19, 2003
Will have 100 different drugs in the next 3 or 4 years. Have enormous cash flow. Paying down their debt. Debt/equity ratio is quite strong. Weak US$ will be of benefit as they are international. 2% dividend.
Photo of Bob StodgellBob Stodgell
Owned
Unlock Rating
$34.18

Stock price when the opinion was issued

$27.72

As of Sep 14, 2026. Market Open.

biotechnologypharmaceutical
BUY

Pfizer Inc(PFE)

Oct 27, 2003
Pharmaceutical sector has been very frustrating. OK buy for a long-term investment. Could still be some downside. Expecting to file 22 to 25 new drugs between now and 2006. Generates tremendous cash flow. Earnings visibility is good.
Photo of Stephane RochonStephane RochonUnlock Rating
$30.97

Stock price when the opinion was issued

$27.72

As of Sep 14, 2026. Market Open.

biotechnologypharmaceutical
PAST TOP PICK

Pfizer Inc(PFE)

Oct 15, 2003
(A top pick Sep 19/03. Down 1.8%.) Still likes the area and this is the premier company.
Photo of Laura WallaceLaura Wallace
Owned
Unlock Rating
$30.60

Stock price when the opinion was issued

$27.72

As of Sep 14, 2026. Market Open.

biotechnologypharmaceutical
BUY

Pfizer Inc(PFE)

Oct 03, 2003
Drug industry has been experiencing difficulties over the past 12 months. Thinks the industry has growth going forward.
Photo of Ray SteeleRay SteeleUnlock Rating
$30.78

Stock price when the opinion was issued

$27.72

As of Sep 14, 2026. Market Open.

biotechnologypharmaceutical
DON'T BUY

Pfizer Inc(PFE)

Sep 29, 2003
Viagra is about to have its first major competitor, which could be a significant threat. Pharmaceutical industry suffers from trademark litigations.
Photo of David BaskinDavid BaskinUnlock Rating
$30.89

Stock price when the opinion was issued

$27.72

As of Sep 14, 2026. Market Open.

biotechnologypharmaceutical
DON'T BUY

Pfizer Inc(PFE)

Sep 26, 2003
One of the best pharmaceutical companies but have concerns about pharmaceutical companies because of a lot of pressure on prices. The pipeline, two to three years out looks pretty thin.
Photo of Jonathen Wellum, B. Comm, B. ScJonathen Wellum, B. Comm, B. Sc
Owned
Unlock Rating
$30.56

Stock price when the opinion was issued

$27.72

As of Sep 14, 2026. Market Open.

biotechnologypharmaceutical
WEAK BUY

Pfizer Inc(PFE)

Sep 25, 2003
Has a strong pipeline and strong products. They've taken some write-offs of Pharmacia from their balance sheet. Model price is $36/37.
Photo of Brian Acker, CABrian Acker, CAUnlock Rating
$30.53

Stock price when the opinion was issued

$27.72

As of Sep 14, 2026. Market Open.

biotechnologypharmaceutical
BUY

Pfizer Inc(PFE)

Sep 23, 2003
Investors are worried about generic drugs coming in. Likes the sector and likes the valuation.
Photo of John ZechnerJohn Zechner
Owned
Unlock Rating
$31.60

Stock price when the opinion was issued

$27.72

As of Sep 14, 2026. Market Open.

biotechnologypharmaceutical
TOP PICK

Pfizer Inc(PFE)

Sep 19, 2003
The big pharmas are trading at low multiples. Trading at 15 X 2004 earnings. Great value.
Photo of Laura WallaceLaura Wallace
Owned
Unlock Rating
$31.45

Stock price when the opinion was issued

$27.72

As of Sep 14, 2026. Market Open.

biotechnologypharmaceutical
TOP PICK

Pfizer Inc(PFE)

Sep 18, 2003
One of the premier drug companies in the world. Good dividend. Generates a lot of cash. Have 20 new drugs that they'll be releasing. Good price.
Photo of Bob StodgellBob Stodgell
Owned
Unlock Rating
$32.05

Stock price when the opinion was issued

$27.72

As of Sep 14, 2026. Market Open.

biotechnologypharmaceutical
Showing 751 to 765 of 890 entries

Build your watch list

Sign in to track investments
you care about

Latest Buy Signals

BUG 4.44$44.48
GS -40.73$988.45
NFLX 2.92$80.32
DAL -0.11$79.8
DML.TO -0.16$4.03
The ultimate 360° Tracker Your financial life in one place, automaticallywealthica-video

Today's Top Picks

CP.TO 1.15$124.99
VRT -18.06$239
NVDA -7.33$210.96
TSM -15.23$418.01
JPM -6.1$350.13

Popular Articles

Latest Sell Signals

AVGO -17.27$344.72
APP 10.28$334.24
XRE.TO 0.05$15.73
ORCL -5.49$144.79
ORCL -5.49$144.79

Most Recent Experts

Liz Young, Head of investment strategy at SoFi

Liz Young, Head of investment strategy at SoFi

SoFi

Stephen Weiss, Founder, Short Hills Capital Partners

Stephen Weiss, Founder, Short Hills Capital Partners

Short Hills Capital Partners

Jim Lebenthal

Jim Lebenthal

Cerity Partners

Joe Terranova

Joe Terranova

Virtus Investment Partners

Larry Berman CFA, CMT, CTA

Larry Berman CFA, CMT, CTA

ETF Capital Management Inc.

disclaimer

Stockchase, in its reporting on what has been discussed by individuals on business television programs (in particular Business News Network), neither recommends nor promotes any investment strategies.

We paraphrase the experts by hand, we watch the shows and write down what we understood from the experts’ comments. We are human and can make mistakes, help us fix any errors. If you see something that you know is not right or if there is a problem with the site, feel free to email us at: [email protected].

About usHow to useContact Us
More...
AdvertisingIn the newsPrivacy PolicyTerms of service
FacebookX
© 2000 - 2026 Stockchase Inc. by Wealthica

You may also like